Faculty profile
Tommy Alfaro Moya
Back to facultyResearch
Read how they describe their research on their University of Toronto profile.
Latest papers
Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.
Transplantation and cellular therapy · 2026
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
JCO oncology practice · 2026
Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.
Transplantation and cellular therapy · 2026
18 publications.
Ferritin as a Pre-Transplant Biomarker for Post-Transplant Outcomes in Allogeneic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide.
Rodriguez-Rodriguez S, Chiarello C, Desai N, Remberger M, Chen C, Al-Shaibani E, Alfaro Moya T, Law AD, Pasic I, Viswabandya A, Michelis FV, Kim DDH, Kumar R, Mattsson J, Novitzky-Basso I
Impact of Graft-Versus-Host Disease Prophylaxis on Long-Term Outcomes in Patients Surviving Beyond Two Years After Allogeneic Transplantation.
Desai N, Rodriguez-Rodriguez S, Chen C, Al-Shaibani E, Alfaro Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD
Prior Malignancy History and Risk of Second Malignancies After Allogeneic Hematopoietic Cell Transplantation.
Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV
HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.
Salas MQ, Alfaro Moya T, Pasic I, Baile González M, Gómez MA, Fox L, Pérez Artigas MDM, Santamaría A, Quintela González MDC, Sánchez Salinas A, Salmerón Camacho JM, Illana Álvaro V, Abdallahi-Lefdil Z, Navascues JC, Pardo L, Fernández-Luis S, Vega Suárez LP, Villar S, Beorlegui-Murillo P, Esquirol A, Izquierdo García I, Mussetti A, Lavilla E, Lopez-Marín J, Filaferro S, Balsalobre P, Bento L, Law A, Viswabandya A, Michelis FV, Mattsson J, Alibhai S, Rovira M, Wang Kim DD, Sureda A, Kumar R
Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.
Rodriguez-Rodriguez S, Desai N, Chen C, Jamani K, Sohier-Poirier C, Lemieux C, White J, Elemary M, Kennah M, Alfaro Moya T, Al-Shaibani E, Novitzky-Basso I, Pasic I, Law AD, Michelis FV, Viswabandya A, Kumar R, Mattsson J, Kim DDH
A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation.
Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, Alfaro Moya T, Law AD, Novitzky-Basso I, Pasic I, Michelis FV, Kumar R, Kim DDH, Mattsson J, Viswabandya A
Effect of Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide on Graft-Versus-Host Disease Outcomes in Female Donor-to-Male Recipient Matched Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Leukemia.
Desai N, Rodriguez-Rodriguez S, Remberger M, Al-Shaibani E, Alfaro-Moya T, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DDH, Kumar R, Mattsson J, Law AD
Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival.
Rodriguez-Rodriguez S, Desai N, Lemieux C, Vachon K, Jamani K, Elemary M, Alfaro-Moya T, Al-Shaibani E, Pasic I, Novitzky-Basso I, Michelis F, Viswabandya A, Kumar R, Mattsson J, Law A, Lachance S, Kim DDH
Conditioning Regimens for Second Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Graft Failure.
Desai N, Rodriguez SR, Chen C, Atenafu EG, Alfaro-Moya T, Law AD, Al-Shaibani E, Novitzky-Basso I, Pasic I, Michelis FV, Viswabandya A, Kim DD, Mattsson J, Kumar R
Impact of graft-versus-host disease prophylaxis on second primary malignancies after allogeneic haematopoietic stem cell transplantation.
Desai N, Al-Shaibani E, Alfaro-Moya T, Law AD, Lam W, Remberger M, Pasic I, Novitzky-Basso I, Viswabandya A, Kim DD, Kumar R, Lipton JH, Mattsson J, Michelis FV
Frequent collaborators
- Jonas Mattsson and Rajat Kumar: 91 shared papers
- Jonas Mattsson and Tommy Alfaro Moya: 18 shared papers
- Rajat Kumar and Tommy Alfaro Moya: 16 shared papers
- Shabbir Alibhai and Jonas Mattsson: 3 shared papers
- Shabbir Alibhai and Rajat Kumar: 3 shared papers
- Jonas Mattsson and Michael Kennah: 2 shared papers
- Shabbir Alibhai and Tommy Alfaro Moya: 1 shared paper
- Li Zhang and Arthur Mortha: 1 shared paper
- Li Zhang and Jonas Mattsson: 1 shared paper
- Li Zhang and Tommy Alfaro Moya: 1 shared paper
- Arthur Mortha and Jonas Mattsson: 1 shared paper
- Arthur Mortha and Tommy Alfaro Moya: 1 shared paper
- Rajat Kumar and Michael Kennah: 1 shared paper
- Michael Kennah and Tommy Alfaro Moya: 1 shared paper
- Department of Medicine
- Department of Immunology
- Laboratory Medicine & Pathobiology
- Li Ka Shing Knowledge
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Jonas Mattsson
Faculty
18 shared papers, latest 2026
Rajat Kumar
Faculty
16 shared papers, latest 2026
Shabbir Alibhai
Li Ka Shing Knowledge
1 shared papers, latest 2026
Li Zhang
Laboratory Medicine & Pathobiology
1 shared papers, latest 2025
Arthur Mortha
Department of Immunology
1 shared papers, latest 2025
Michael Kennah
Faculty
1 shared papers, latest 2025
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.